UNION therapeutics announces presentation of preliminary data from Phase 2a investigator-initiated study with orismilast in ulcerative colitis at the 20th ECCO Congress

Poster presentation of preliminary data from the Phase 2a investigator-initiated study UCORIS in ulcerative colitis (UC) at the 20th ECCO CongressUC is a chronic inflammatory bowel disease that causes inflammation and ulcers (sores) in the lower digestive tract with limited efficacious treatment options availableOrismilast is a high-potency PDE4B/D inhibitor with broad anti-inflammatory properties in development for oral treatment of inflammatory diseases, including hidradenitis suppurative (HS)& Warren R.B. et al., Efficacy and safety in moderate-severe psoriasis and development of modified release tablets, JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18812Warren R.B. et al., Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS), J Am Acad Dermatol 2024: https://pubmed.ncbi.nlm.nih.gov/37951245/ & Silverberg J.I. et al., Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS), Br J Dermatol 2025: https://pubmed.ncbi.nlm.nih.gov/39847538/. Frederiksen et al., JEADV 2023: https://pubmed.ncbi.nlm.nih.gov/38147438/.

Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com

About UNION therapeutics

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching multiple marketed drugs. Read more at www.uniontherapeutics.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-presentation-of-preliminary-data-from-phase-2a-investigator-initiated-s,c4109415

 

View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-announces-presentation-of-preliminary-data-from-phase-2a-investigator-initiated-study-with-orismilast-in-ulcerative-colitis-at-the-20th-ecco-congress-302382223.html